Tyrosine Protein Kinase Receptor TYRO3 (Tyrosine Protein Kinase BYK or Tyrosine Protein Kinase DTK or Tyrosine Protein Kinase RSE or Tyrosine Protein Kinase TIF or Tyrosine Protein Kinase SKY or TYRO3 or EC 188.8.131.52) - Tyrosine-protein kinase receptor TYRO3 is an enzyme encoded by the TYRO3 gene. TYRO3 activates the AKT survival pathway, including nuclear translocation of NF-kappa-B and up-regulation of transcription of NF-kappa-B-regulated genes.
TYRO3 signaling plays an important role in various processes such as neuron protection from excitotoxic injury, platelet aggregation, cytoskeleton reorganization, inhibition of Toll-like receptors (TLRs)-mediated innate immune response by activating STAT1, which selectively induces production of suppressors of cytokine signaling SOCS1 and SOCS3. The molecules developed by companies in IND/CTA Filed and Preclinical stages are 1 and 3 respectively.
Click here for sample report @ https://www.wiseguyreports.com/sample-request/2967009-tyrosine-protein-kinase-receptor-tyro3-tyrosine-protein-kinase-byk-or
Top Companies mentioned
Celldex Therapeutics Inc
Elsalys Biotech SAS
Qurient Co Ltd
Tyrosine Protein Kinase Receptor TYRO3 Industry Major Outlook
Pharmaceutical and Healthcare latest pipeline guide Tyrosine Protein Kinase Receptor TYRO3 - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Tyrosine Protein Kinase Receptor TYRO3, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Tyrosine Protein Kinase Receptor TYRO3 pipeline guide also reviews of key players involved in therapeutic development for Tyrosine Protein Kinase Receptor TYRO3 and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical, Discovery and Unknown stages are 3, 8, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 2 molecules, respectively.
Tyrosine Protein Kinase Receptor TYRO3 - Competitive Analysis
Key players are making innovative developments in Tyrosine Protein Kinase Receptor TYRO3 industry. The same will help in improving the market performance. Heavy investments are made by major players in the R&D sector
The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase Receptor TYRO3
The report reviews Tyrosine Protein Kinase Receptor TYRO3 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.
The report reviews key players involved in Tyrosine Protein Kinase Receptor TYRO3 targeted therapeutics and enlists all their major and minor projects.
The report assesses Tyrosine Protein Kinase Receptor TYRO3 targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type.
The report summarizes all the dormant and discontinued pipeline projects.
For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/2967009-tyrosine-protein-kinase-receptor-tyro3-tyrosine-protein-kinase-byk-or
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.
Partner Relations & Marketing Manager
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)